The opposite effect was observed in cells that were deficient for the tuberous sclerosis complex (TSC; an endogenous negative regulator of mTOR activity), in which mTOR is hyperactive: Tsc2 − ...

Cassava's strong liquidity with $128.6 million in cash supports early-stage development, yet long-term funding needs may lead ...

Current treatments, including antiepileptic drugs, mTOR analogs and surgery, are not fully effective, are associated with serious adverse events and/or are invasive. 1 Initially, Cassava will focus on ...

Detailed price information for Cassava Sciences Inc (SAVA-Q) from The Globe and Mail including charting and trades.